“Tilapia Skin” is the big winner of the Euro Award and takes the €500,000 prize
Published in: September 24, 2020
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, September 2020 – With a total of 1,655 projects submitted in Brazil and more than 15,000 voting physicians, Eurofarma announces the big winner of the Euro Innovation in Health Award: Dr. Edmar Maciel, from the state of Ceará, with the project “Tilapia Skin: A New Biomaterial for Treating Burns, Wounds, Gynecological Surgeries, and Regenerative Medicine.” The announcement was made on the night of September 24 at a virtual event attended by several guests. The doctor has been studying the use of tilapia skin in burn treatment since 2014, and has been expanding studies in several other medical-surgical specialties. The project has shown the versatility of tilapia skin as a new biomaterial with multiple applications.
“I’m very happy with this achievement. Brazil has never had animal skin to treat burned and injured patients, and the products we’re studying and developing are exported by our country at a high cost, thus often not reaching the poorest parts of the population. We’re finalizing the negotiation process so that a company can register the product with ANVISA (National Health Surveillance Agency), and then produce and market it at a large scale, even for use in the international market,” the doctor said.
“In an atypical year like this, because of the coronavirus pandemic, we want to highlight the good things that are happening. Eurofarma’s constant support for innovation and projects that bring concrete benefits to Brazilian society’s quality of life is a fundamental part of its DNA. We’re very proud to have made this award possible and reaffirmed our commitment to encouraging the medical community to create more projects that will improve patient care and care for life,” said Roberta Junqueira, Commercial Director at Eurofarma, the exclusive sponsor of the Euro Award.
The award ceremony was marked by great moments, with videos showed how the 11 finalist initiatives made a difference. For 1h30, artistic performances representing the continents made an analogy that medicine and innovation know no boundaries. The night ended with a special concert.
The Euro Innovation in Health Award aims to recognize and offer incentive to the search for solutions in innovative products, services, and actions that have a strong social impact in the country. Dr. Edmar Maciel will receive the corresponding amount to €500,000.00 (five hundred thousand euros) in Brazilian reais. The other 10 finalist initiatives will each receive the corresponding amount to fifty thousand euros (€50,000.00) in Brazilian reais, totaling one million euros (€1,000,000.00).
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab
“I’m very happy with this achievement. Brazil has never had animal skin to treat burned and injured patients, and the products we’re studying and developing are exported by our country at a high cost, thus often not reaching the poorest parts of the population. We’re finalizing the negotiation process so that a company can register the product with ANVISA (National Health Surveillance Agency), and then produce and market it at a large scale, even for use in the international market,” the doctor said.
“In an atypical year like this, because of the coronavirus pandemic, we want to highlight the good things that are happening. Eurofarma’s constant support for innovation and projects that bring concrete benefits to Brazilian society’s quality of life is a fundamental part of its DNA. We’re very proud to have made this award possible and reaffirmed our commitment to encouraging the medical community to create more projects that will improve patient care and care for life,” said Roberta Junqueira, Commercial Director at Eurofarma, the exclusive sponsor of the Euro Award.
The award ceremony was marked by great moments, with videos showed how the 11 finalist initiatives made a difference. For 1h30, artistic performances representing the continents made an analogy that medicine and innovation know no boundaries. The night ended with a special concert.
The Euro Innovation in Health Award aims to recognize and offer incentive to the search for solutions in innovative products, services, and actions that have a strong social impact in the country. Dr. Edmar Maciel will receive the corresponding amount to €500,000.00 (five hundred thousand euros) in Brazilian reais. The other 10 finalist initiatives will each receive the corresponding amount to fifty thousand euros (€50,000.00) in Brazilian reais, totaling one million euros (€1,000,000.00).
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarmalab | Twitter: @eurofarmaLab